Form 4: Castle Biosciences Director Tiffany Olson Acquires Restricted Stock Units

Director Tiffany Olson acquired 8,673 Restricted Stock Units (RSUs) of Castle Biosciences Inc. on May 23, 2024, which vest in full on May 23, 2025.

Summary

• On May 23, 2024, Tiffany Olson, a director of Castle Biosciences Inc., acquired 8,673 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Castle Biosciences' Common Stock.
• The RSUs vest in full on the one-year anniversary of the grant date, which is May 23, 2025.
• Following the transaction, Olson directly owns 8,673 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of RSUs by a director is generally seen as a positive sign, but without additional context, the impact is limited.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs in May 2025 could potentially increase the number of outstanding shares of Castle Biosciences.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the acquisition of RSUs by a director as a positive sign of confidence in the company's future.

Key Dates